December 2025 in “Rare Metals” This review assesses the potential of smart dressings, engineered to respond to various stimuli, as advanced treatments for chronic inflammatory skin diseases by examining their activation mechanisms and proposing future developments like integrating AI and closed-loop monitoring for adaptive therapy.
December 2022 in “International Journal of Molecular Sciences” This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.
January 2024 in “Wiadomości Lekarskie” In this study, the integration of artificial intelligence in medicine was discussed, highlighting its potential to enhance diagnostic processes, optimize therapies, and provide advanced patient monitoring despite challenges like data inconsistency and limited model transparency.
April 2026 in “Journal of Pharmaceutical and BioTech Industry” This review highlights recent advances in personalized transdermal drug delivery systems, noting their potential for improved treatment efficacy and safety, but identifies significant challenges in clinical translation.
March 2026 in “Preprints.org” This review suggests that the compound DRDE-07, originally a sulphur-mustard countermeasure candidate, could potentially be repurposed for skin protection due to its compatibility with pathways involved in oxidative stress and inflammation, though further experimental study is needed to confirm its therapeutic applicability in dermatology.
